BioLineRx: Pharmacoeconomic Study Shows Cost Benefits Of Using Motixafortide With G-CSF

(RTTNews) - BioLineRx Ltd. (BLRX) reported positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization agent on top of granulocyte colony stimulating factor, versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation.

"The compelling cost savings identified by this rigorously designed study strongly support the company's view that Motixafortide, in combination with G-CSF, can become the new standard of care as an upfront, or primary, therapy for all multiple myeloma patients undergoing autologous stem cell transplantation," said Philip Serlin, CEO.

BioLineRx said it remains on track to submit a New Drug Application to the FDA in the first half of next year.